Plasma osteopontin is correlated with bone resorption markers in rheumatoid arthritis patients

International Journal of Rheumatic Diseases

Volumn 17, Issue 1, 2014, Pages 50-56

  Iwadate, Haruyo ^a   Kobayashi, Hiroko ^a   Kanno, Takashi ^b   Asano, Tomoyuki ^a   Saito, Rie ^a   Sato, Shuzo ^a   Suzuki, Eiji ^a   Watanabe, Hiroshi ^a   Ohira, Hiromasa ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b OHTA NISHINOUCHI HOSPITAL   (Japan)

Author keywords

CTX 1; Osteopontin; Rheumatoid arthritis; TRACP 5b

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ADALIMUMAB; AUROTHIOMALATE; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BUCILLAMINE; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOPONTIN; PREDNISOLONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; STROMELYSIN; TACROLIMUS; THROMBIN; TOCILIZUMAB;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN URINE LEVEL; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; VERY ELDERLY;

CTX-1; OSTEOPONTIN; RHEUMATOID ARTHRITIS; TRACP 5B;

ACID PHOSPHATASE; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; BONE RESORPTION; COLLAGEN TYPE I; DISABILITY EVALUATION; FEMALE; HUMANS; ISOENZYMES; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; OSTEOPONTIN; PEPTIDES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84893699415     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12115     Document Type: Article

References (32)

1. Uede T (2011) Osteopontin, intrinsic tissue regulator of intractable inflammatory diseases. Pathol Int 61, 265-80.
2. Sodek J, Chen J, Nagata T et al. (1995) Regulation of osteopontin in osteoblasts. Ann NY Acad Sci 760, 223-41.
3. Ashkar S, Weber GF, Panoutsakopoulou V et al. (2000) Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287, 860-4.
4. Chen G, Zhang X, Li R et al. (2010) Role of osteopontin in synovial Th17 differentiation in rheumatoid arthritis. Arthritis Rheum 62, 2900-8.
5. Kanayama M, Morimoto J, Matsui Y et al. (2011) α9β1 integrin-mediated signaling serves as an intrinsic regulator of pathogenic Th17 cell generation. J Immunol 187, 5851-64.
6. Gravallese EM (2003) Osteopontin: a bridge between bone and the immune system. J Clin Invest 112, 147-9.
7. Sennels HP, Sorensen S, Ostergaard M et al. (2008) Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate. Scand J Rheumatol 37, 241-7.
8. Oshima S, Yamaguchi N, Nishioka K et al. (2002) Enhanced local production of osteopontin in rheumatoid joints. J Rheumatol 29, 2061-7.
9. Hasegawa M, Nakoshi Y, Iino T et al. (2009) Thrombin-cleaved osteopontin in synovial fluid of subjects with rheumatoid arthritis. J Rheumatol 36, 240-5.
10. Shio K, Kobayashi H, Asano T et al. (2010) Thrombin-cleaved osteopontin is increased in urine of patients with rheumatoid arthritis. J Rheumatol 37, 704-10.
11. Garnero P, Rousseau JC, Dermas PD (2000) Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum 443, 953-68.
12. Arnett FC, Edworthy SM, Bloch DA et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31, 315-24.
13. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38, 44-8.
14. Steinblocker O, Traeger CH, Batterman RC (1949) Therapeutic criteria in rheumatoid arthritis. JAMA 140, 659-62.
15. Kon S, Maeda M, Segawa T et al. (2000) Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J Cell Biochem 77, 487-98.
16. Min W, Shiraga H, Chalko C, Goldfarb S, Krishna GG, Hoyer JR (1998) Quantitative studies of human urinary excretion of uropontin. Kidney Int 53, 189-93.
17. Xie DL, Hui F, Meyers R, Homandberg GA (1994) Cartilage chondrolysis by fibronectin fragments is associated with release of several proteinases: stromelysin plays a major role in chondrolysis. Arch Biochem Biophys 311, 205-12.
18. Yamanaka H, Matsuda Y, Tanaka M et al. (2000) Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 43, 852-8.
19. Shinozaki M, Inoue E, Nakajima A et al. (2007) Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA. Mod Rheumatol 17, 403-8.
20. Minkin C (1982) Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 34, 285-90.
21. Yaziji H, Jancklia AJ, Lear SC, Martin AW, Yam LT (1995) Immunohistochemical detection of tartrate-resistant acid phosphatase in non-hematopoietic human tissues. Am J Clin Pathol 104, 397-402.
22. Hayman AR, Bune AJ, Bradley JR, Rashbass J, Cox TM (2000) Osteoclastic tartrate-resistant acid phosphatase (Acp 5): its localization to dendritic cells and diverse murine tissues. J Histochem Cytochem 48, 219-28.
23. Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Vaananen HK (2006) Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab 52, 499-509.
24. Gerdhem P, Ivaska KK, Alatalo SL et al. (2004) Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 19, 386-93.
25. Nenonen A, Cheng S, Ivaska KK et al. (2005) Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 20, 1804-12.
26. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR (1998) Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 152, 943-51.
27. Janckila AJ, Neustadt DH, Yam LT (2008) Significance of serum TRACP in rheumatoid arthritis. J Bone Miner Res 23, 1287-95.
28. Bergmann P, Body JJ, Boonen S et al. (2009) Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract 63, 19-26.
29. Dane C, Dane B, Cetin A, Erginbas M (2008) Effect of risedronate on biochemical marker of boen resorption in postmenopausal women with osteoporosis or osteopenia. Gynecol Endocrinol 24, 207-13.
30. Garnero P, Landewé R, Boers M et al. (2002) Association of baseline levels of markers of ZZbone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 46, 2847-56.
31. Vis M, Havaardsholm EA, Haugeberg G et al. (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65, 1495-9.
32. Ek-Rylander B, Andersson G (2010) Osteoclast migration on phosphorylated osteopontin is regulated by endogenous tartrate-resistant acid phosphatase. Exp Cell Res 316, 443-51.